Solventum Corporation (NYSE: SOLV) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $14.6B. The Maz Rating grades it against the other companies in its sector.
Solventum Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $86.06, Solventum Corporation trades at 97.5x trailing earnings, 1.8x sales and 3.1x book value, with an EV/EBITDA of 24.3. Over the last twelve months it generated about $8.1B of revenue and $150M of net income. It runs a gross margin of 54.3%, an operating margin of 24.6% and a net margin of 1.9%. It shows return on equity of 3.2%, return on invested capital of 16.6% and a free cash flow yield of 0.0%. On the balance sheet: a debt-to-equity ratio of 1.10 and a current ratio of 1.03. Over the past 52 weeks the share price ranged from $62.38 to $94.16, with a beta of 0.75.
Solventum Corporation does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 9 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Solventum Corporation (SOLV) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes Dow Jones, and fails AAOIFI, S&P Global, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 33.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.96% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 33.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.96% / 33% · Receivables / Mkt Cap (36m) 9.13% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 33.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.96% / 33.33% · Receivables / Mkt Cap (24m) 9.13% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 35.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 4.04% / 33.33% · Receivables / Avg Assets (4Q) 8.66% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 35.8% / 33.33% · (Cash+ST Inv) / Total Assets 3.18% / 33.33% · (Cash+Recv) / Total Assets 13.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Solventum Corporation (SOLV) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes Dow Jones, and fails AAOIFI, S&P Global, MSCI and FTSE.
No. Solventum Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
Solventum Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.